Nature Aid parent firm announce annual results

STADA, the company behind Preston's Natures Aid, has announced adjusted group revenues were up by six per cent to €4.3bn, with revenues by STADA’s Specialty segment exceeding €1bn for the first time on 17 per cent growth, driven by biosimilars and innovative medicines.

Group earnings before interest, tax, depreciation and amortization (EBITDA)  ̵  adjusted for special items and at constant exchange rates  ̵  also improved by eight per cent to €961m.

Peter Goldschmidt, STADA chief executive, said: "All our regions - Western Europe, Central & Eastern Europe, Germany and Middle East and Asia - are contributing nicely to our growth.

"Key drivers for our above-industry growth were several great launches across all our three segments. On top of this, we in-licensed in 2025 alone 110 new products securing an even stronger pipeline for a successful future."

The UK is STADA’s second-largest Consumer Healthcare market by sales, and provides a range of further healthcare solutions across its Specialty and Generics business.

Craig Shaw, UK general manager, said: “STADA UK continues to outperform the market across many of our core categories within healthcare where are energised by the growth prospects in 2026 and beyond.”

“Digital marketing and ecommerce are continuing to grow at double-digit levels as we ensure our products are within arm’s reach of our customers’ needs.

"Today, as we publish our results, our Nizoral Anti-Dandruff Treatment Shampoo is the number one ranked Shampoo and Conditioner product on Amazon, thanks to its clinically proven formula that treats dandruff from the very first wash.

"Covonia, our cough and cold medicine, is gaining market share following our winter ‘The Bull is Back’ multi-media campaign hitting broadcast TV during the key winter season.

“With our Britannia neurology offering we are dedicated to improving the lives of people with long-term conditions, and providing important support for their families, caregivers, and medical teams. 

"Whilst our Natures Aid Vitamins, Minerals and Supplements business offers a full range of self-care solutions for infants to older people, ensuring STADA is well placed to provide a broad treatment portfolio for a wide range of healthcare needs in the UK.”

In March Natures Aid launched the UK’s first range for Bluey vitamins to help support everyday health, immune and bone health in children from aged three.

The range is being sold through Boots, Morrisons, Holland and Barrett and key online retailers such as Ocado and Amazon.

The Natures Aid site produced an impressive 6.5m packs of vitamins and supplements.

STADA also continues to play a leading role as a supplier of dermatology creams to the NHS.

In the prescription-only sector, the company continues to offer a range of therapeutic options with respiratory inhalers, an ustekinumab biosimilar in immunology, and an orphan medicine for rare and debilitating kidney disease IgA-Nephropathy (IgAN).